S
Steven K. Albanese
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 16
Citations - 650
Steven K. Albanese is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: ABL & Kinase. The author has an hindex of 8, co-authored 16 publications receiving 410 citations. Previous affiliations of Steven K. Albanese include Schrödinger & Kettering University.
Papers
More filters
Journal ArticleDOI
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Andrew M. Intlekofer,Alan H. Shih,Bo Wang,Abbas Nazir,Ariën S. Rustenburg,Steven K. Albanese,Minal Patel,Christopher Famulare,Fabian Correa,Naofumi Takemoto,Vidushi Durani,Hui Liu,Justin Taylor,Noushin Farnoud,Elli Papaemmanuil,Justin R. Cross,Martin S. Tallman,Maria E. Arcila,Mikhail Roshal,Gregory A. Petsko,Bin Wu,Sung Choe,Zenon D. Konteatis,Scott A. Biller,John D. Chodera,Craig B. Thompson,Ross L. Levine,Eytan M. Stein +27 more
TL;DR: A new mechanism of acquired clinical resistance in two patients with acute myeloid leukaemia driven by mutant IDH2 is described, in which a second-site mutation on the wild-type allele induces therapeutic resistance to IDH1 inhibitor ivosidenib.
Journal ArticleDOI
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu,Can G. Pham,Steven K. Albanese,Yiyu Dong,Toshinao Oyama,Chung-Han Lee,Vanessa Rodrik-Outmezguine,Zhan Yao,Song Han,David J. Chen,Daniel L. Parton,John D. Chodera,Neal Rosen,Emily H. Cheng,James J. Hsieh +14 more
TL;DR: In this paper, the authors identified three distinct mechanisms of hyperactivation, including reduced binding to DEP domain-containing MTOR-interacting protein (DEPTOR), resistance to regulatory associated protein of mTOR-mediated (RAPTOR)-mediated) suppression, and altered kinase kinetics.
Journal ArticleDOI
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
Gerard Minuesa,Steven K. Albanese,Wei Xie,Yaniv Kazansky,Daniel Worroll,Arthur Chow,Alexandra Schurer,Sun Mi Park,Christina Z. Rotsides,James Taggart,Andrea Rizzi,Andrea Rizzi,Levi N. Naden,Timothy Chou,Saroj Gourkanti,Daniel Cappel,Maria C. Passarelli,Maria C. Passarelli,Lauren Fairchild,Lauren Fairchild,Carolina Adura,Fraser Glickman,Jessica Schulman,Christopher Famulare,Minal Patel,Joseph K. Eibl,Gregory M. Ross,Shibani Bhattacharya,Derek S. Tan,Christina S. Leslie,Thijs Beuming,Dinshaw J. Patel,Yehuda Goldgur,John D. Chodera,Michael G. Kharas +34 more
TL;DR: This study finds that the small molecule Ro 08–2750 (Ro) binds directly and selectively to MSI2 and competes for its RNA binding in biochemical assays and provides a framework for targeting RNA binding proteins in cancer.
Journal ArticleDOI
Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations.
Kevin Hauser,Christopher Negron,Steven K. Albanese,Soumya S. Ray,Thomas Steinbrecher,Robert Abel,John D. Chodera,Lingle Wang +7 more
TL;DR: Alchemical free-energy calculations to predict how kinase mutations modulate inhibitor affinities to Abl, a major target in chronic myelogenous leukemia, have useful accuracy in predicting resistance for eight FDA-approved kinase inhibitors across 144 clinically identified point mutations.
Journal ArticleDOI
A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation
Emily F. Ruff,Joseph M. Muretta,Andrew R. Thompson,Eric W. Lake,Soreen Cyphers,Steven K. Albanese,Sonya M. Hanson,Julie M. Behr,Julie M. Behr,David D. Thomas,John D. Chodera,Nicholas M. Levinson +11 more
TL;DR: A battery of spectroscopic methods are used to show that the ~100 fold activation of the mitotic kinase Aurora A by phosphorylation occurs without a population shift from the DFG-Out to the D FG-In state, and that the activation loop of the activated kinase remains highly dynamic.